Cidara Therapeutics (id:5624 CDTX)

20.40 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:06:24 AM)

Exchange closed, opens in 1 day 22 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• 5 years
• All

About Cidara Therapeutics

Market Capitalization 94.78M

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.